Capricor Therapeutics Inc (CAPR.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2013||Independent Executive Chairman of the Board|
|51||2014||President, Chief Executive Officer, Director|
|32||2018||Chief Financial Officer, Principal Accounting Officer|
|62||2013||Executive Vice President, General Counsel|
|61||2015||Vice President - Regulatory Affairs and Drug Development|
- BRIEF-Capricor Q4 Earnings Per Share $0.42
- BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation
- BRIEF-Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
- BRIEF-Capricor Therapeutics Announces Issuance Of Key U.S. Patent On Exosome Technology
- BRIEF-Capricor & California Institute For Regenerative Medicine Entered Into Amendment 3 To CIRM Notice Loan Award